Alligator Bioscience AB is characterized by its core values of innovation, scientific excellence, and patient focus. With a strong corporate philosophy, Alligator Bioscience AB strives to improve the lives of patients by developing innovative antibody-based immunotherapies. The company is dedicated to conducting groundbreaking research, utilizing cutting-edge technologies, and collaborating with key stakeholders to address unmet medical needs in oncology. Alligator Bioscience AB emphasizes integrity, transparency, and teamwork in its pursuit of novel therapeutics that have the potential to make a significant impact on the treatment of cancer.

Alligator Bioscience AB is primarily present in Sweden.

Alligator Bioscience AB has achieved several significant milestones. The company successfully advanced its lead immune-oncology drug, ATOR-1017, into Phase I clinical trials. Additionally, Alligator Bioscience AB formed a strategic partnership with Aptevo Therapeutics to jointly develop and commercialize ALG.APV-527, a bispecific antibody-based immunotherapy. Furthermore, the company expanded its pipeline by initiating the preclinical development of ATOR-1015, another promising immune-oncology candidate. These accomplishments showcase Alligator Bioscience AB's dedication to advancing innovative therapies in the field of cancer treatment, solidifying its position as a notable player in the biotechnology sector.

Alligator Bioscience AB is a renowned Swedish biotechnology company specializing in the development of innovative antibody-based immunotherapies for cancer treatment. Founded in 2001, Alligator Bioscience has built a strong expertise in discovering and developing next-generation antibodies known as tumor-directed immunomodulators. With a focus on creating novel treatment options that harness the body's immune system to fight cancer, Alligator Bioscience has established itself as a key player in the biopharmaceutical industry. The company has forged strategic collaborations with several leading pharmaceutical companies and continues to drive advancements in cancer immunotherapy.

The main competitors of Alligator Bioscience AB in the market are biotechnology companies and pharmaceutical companies that focus on the development of novel immunotherapies and anticalins. Some notable competitors of Alligator Bioscience AB include Agenus Inc., argenx SE, Bavarian Nordic A/S, and Genmab A/S.

Alligator Bioscience AB primarily operates in the biotechnology and pharmaceutical industries.

The business model of Alligator Bioscience AB is focused on developing innovative antibody-based drugs to address unmet medical needs in cancer treatment. Alligator Bioscience utilizes its proprietary discovery platform, called the FIND technology, to identify potential drug candidates and enhance their effectiveness. By collaborating with leading pharmaceutical companies, Alligator Bioscience seeks to leverage its expertise and technologies to bring novel therapeutics to market. Through strategic partnerships and licensing agreements, the company aims to generate revenues and maximize shareholder value. Alligator Bioscience's business model centers on pioneering research and development efforts in the field of immuno-oncology to ultimately improve patients' lives.

Alligator Bioscience KGV ir -1,59.

Alligator Bioscience KUV ir 1,32.

AlleAktien kvalitātes vērtējums Alligator Bioscience ir 4/10.

gaidāmā Alligator Bioscience apgrozījums ir 245,14 milj. SEK.

gaidāmā Alligator Bioscience peļņa ir -203,00 milj. SEK.

Alligator Bioscience AB is a Swedish company specializing in the research and development of antibodies and immuno-oncology. The company's business model focuses on creating customer-oriented solutions that contribute to improving patient health and the pharmaceutical industry. Alligator Bioscience offers two main categories of products: 1. Immuno-oncology products 2. Advanced immunostimulants Alligator Bioscience is particularly known for its immuno-oncology products, which are specifically designed to fight cancer. These products are based on blocking specific antibodies that allow cancer cells to invade healthy tissue. In doing so, Alligator Bioscience contributes to the development of new therapies that can effectively and rapidly combat cancer cells and improve patients' quality of life. Alligator Bioscience's advanced immunostimulants are based on combining antibodies and molecules (such as immune checkpoint modulators) to influence and control immune responses. These immunomodulating antibodies can be used for both cancer treatment and the treatment of autoimmune diseases. Alligator Bioscience follows an "open innovation" strategy, focusing on collaboration with partners from the pharmaceutical industry and academic institutions. This allows Alligator Bioscience to advance its research and development by leveraging the knowledge and resources of its strategic partners. The company also has a strong development and innovation department that is dedicated to advancing the discovery and development of new drugs and technologies. Alligator Bioscience continuously invests in supplementing its pipelines through collaborations, licensing agreements, and acquisitions. Alligator Bioscience has built a strong network of partners, including biotech and pharmaceutical companies that further develop and market the products and solutions of Alligator Bioscience. The company also collaborates with contract research organizations and other institutions in the science and technology field. Furthermore, Alligator Bioscience plans to expand into international markets to increase its revenue and global presence. With its strong focus on researching and developing new technologies and drugs, Alligator Bioscience is well-positioned to remain a leader in the industry and deliver new discoveries and products. Overall, Alligator Bioscience is an innovative company specializing in the research and development of new technologies and products in immuno-oncology. With its open innovation strategy, strong development and innovation department, and broad network of partners, Alligator Bioscience aims to revolutionize the field of cancer treatment through the development of innovative therapies.

Alligator Bioscience izmaksā dividendes 0 SEK, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Alligator Bioscience vai uzņēmums nedod dividendes.

Alligator Bioscience ISIN ir SE0000767188.

Alligator Bioscience WKN ir A2AN1Z.

Alligator Bioscience simbols ir ATORX.ST.

Pēdējo 12 mēnešu laikā Alligator Bioscience maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Alligator Bioscience plāno maksāt dividendes 0 SEK apmērā.

Alligator Bioscience pašreizējā dividendu rentabilitāte ir .

Alligator Bioscience maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Alligator Bioscience pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 SEK. Tas atbilst dividendes ražībai 0 %.

Alligator Bioscience tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Alligator Bioscience apmērā 0 SEK, kas tika izmaksāta 6.11.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 6.11.2024..

Pēdējās dividendes izmaksa notika 6.11.2024..

Gadā 2023, Alligator Bioscience izmaksāja 0 SEK dividendes.

Alligator Bioscience dividendes tiek izmaksātas SEK.